News | November 14, 2022
Biocon Biologics features on ASIA IP ELITE List 2022
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
Subscribe To Our Newsletter & Stay Updated
